Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1186/s13075-015-0578-5
Published Online: 2015-03-19
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Warren, Marshelle S
Hughes, Steven G
Singleton, Walter
Yamashita, Mason
Genovese, Mark C
License valid from 2015-03-19